Potassium and norepinephrine- or angiotensin–mediated pressor control in pre-hypertension  by Bianchetti, Mario G. et al.
Kidney International, Vol. 31(1987), pp. 956—963
CLINICAL INVESTIGATION
Potassium and norepinephrine- or angiotensin—mediated
pressor control in pre-hypertension
MARIO G. BIANCHETTI, PETER WEIDMANN, CARLO BERETTA—PICCOLI, and CLAUDIA FERRIER
Medizinische Poliklinik, University of Berne, Switzerland
Potassium and norepinephrine- or angiotensin—mediated pressor con-
trol in pre-hypertension. Blood pressure (BP), plasma electrolytes,
renin, aldosterone, angiotensin II (A!!) or catecholamines, the chrono-
tropic effects of intravenous isoproterenol, norepinephrine (NE) or All,
the pressor responses to NE or All, and the relationship between
plasma All and aldosterone concentrations were studied before and
after 10 days of dietary supplementation with potassium 100 mmol/day,
in normotensive members of normotensive (N = 12) or hypertensive (N
= 12) families, and 11 patients with borderline essential hypertension.
Under control conditions, the pressor responsiveness to NE was
significantly enhanced in normotensive with positive family history for
hypertension and hypertensive subjects; the other variables were
comparable in the groups. After potassium supplementation, plasma
potassium, renin, aldosterone or All, and the relationship between All
and aldosterone levels increased significantly, while body weight,
plasma catecholamines, the chronotropic effects of isoproterenol, All
or NE, the pressor effects of All and plasma clearance of All or NE
were unchanged in all groups. In normotensive members of hyperten-
sive families and patients with hypertension, BP was decreased and the
exaggerated pressor responsiveness to NE was normalized; these
variables were not modified in normotensive members of normotensive
families. These observations are consistent with a potassium—remedi-
able disturbance in NE- but not All-dependent regulation of BP in the
pathogenesis of essential hypertension.
Potassium (K) is involved in the regulation of blood pres-
sure (BP) and perhaps also in the pathogenesis of essential
hypertension. In the experimental animal, dietary K supple-
mentation blunted or even prevented the rise in BP caused by
DOCA [1] or a high sodium intake [2—4] in spontaneously
hypertensive rats [5]. In humans a high K diet may reduce BP
in normotensive offspring of hypertensive families [6—8] and
improve established essential hypertension [6, 8—12]. More-
over, the antihypertensive effect of K is particularly apparent
on a high and blunted on a low sodium diet [12].
The BP-lowering mechanisms of dietary K supplementation
during high sodium intake are poorly understood. The regula-
tory abnormality that already exists in many normotensive
offspring of hypertensive families is at least in part character-
ized by an exaggerated cardiovascular reactivity to norepineph-
rifle (NE) in the presence of normal plasma catecholamine,
renin and angiotensin II (All) levels, unaltered responsiveness
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of BP and plasma aldosterone to All, and a yet normal blood
volume and exchangeable sodium [13—15]. In borderline or
established essential hypertension, the disturbance in norad-
renergic reactivity [16—19] may be complemented further by a
tendency for slightly—increased plasma catecholamine concen-
trations [20] and probably a secondary increase in BP-respon-
siveness to All [18], while aldosterone responses to All were
variably found to be enhanced [21], normal [22, 23] or even
blunted [24].
Previous reports suggested that an increase in dietary K
intake may promote its antihypertensive action by enhancing
natriuresis [3, 9], modulating barorefiex sensitivity [7], direct
vasodilatation [3, 25] or lowering cardiovascular reactivity to
NE [8] or All [26]. The effects of a high K intake on
All-mediated BP control and aldosterone responsiveness have
not been assessed simultaneously with noradrenergic BP con-
trol. Such an aproach was chosen for the present investigation
in young untreated patients with borderline essential hyperten-
sion and normotensive subjects with a negative or positive
family history of essential hypertension (FHH).
Methods
Twelve, healthy normotensive volunteers with a negative
FHH, 12 healthy normotensive volunteers with a positive
FHH, and 11 patients with yet untreated essential hypertension
were studied under outpatient conditions. Their age, sex and
body habitus appear in Table 1.
The family tree was constructed carefully for each normoten-
sive subject [13] and information on BP was obtained both by
questioning the subjects and their families as well as directly
from the family doctor and their medical records, The FHH was
considered to be positive if at least one of both parents or any
existing sibling had essential hypertension [13, 27]. In the
subjects classified as having a negative FHH, both parents or
any existing sibling had no known previous episodes of high BP,
and a normal BP documented on medical record at least once in
the year preceeding the investigation; there was also no evi-
dence of hypertension in the grandparents of these subjects,
although the latter information was incomplete in two. Parents
or siblings of the normotensive subjects were considered as
hypertensive if their untreated supine or sitting BP was consis-
tently and repeatedly greater than 160/95 mm Hg before age 60
years. In contrast they were considered as normotensive if their
BP was repeatedly less than 140/90 mm Hg before age 65 years
and less than 160/95 mm Hg after age 65 years. The patients
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Table 1. Basal values of blood pressure, electrolytes and endocrine variables under basal dietary conditions or after dietary supplementation
with potassium (mean SD)
Normotensive members of .Patients with borderline
essential hypertensionnormotensive families hypertensive families
basal K high K basal K high K basal K high K
diet diet diet diet diet diet
N 12 12 11
Sex, male/female 7/5 5/7 4/7
Age, years 22.8 3.3
1.73 0.07
22.9 3.4
1.73 0.07
27.3 6.7
1.74 0.11
Weight, kg 62.3 8.5 61.1 9.3 64.3 12.1 64.0 12.2 71.0 11.3 70.5 10.6
Heart rate, supine, beats/mm 63 11 62 6 64 7 62 5 63 8 62 5
Blood pressure, supine, mm Hg
systolic 111 9 110 10 113 8 107 8 132 15d 126 l5
diastolic 70 7 70 10 73 6 70 8 89 9d 84 iia
mean 83 7 83 9 86 6 82 6 103 11" 98 l2
Plasma sodium, mmol/liter 141 2.5 140 1.5 140 2.0 139 2.0 140 1.2 139 2.2
potassium, mmol/liter 3.90 0.16 4.14 0.17" 4.15 0.19 4.35 0.45a 4.20 0.24 4.52 021"
total calcium, mmol/liter 2.21 0.06 2.26 0.06 2.30 0.10 2.29 0.09 2.24 0.10 2.27 0.05
norepinephrine, ng/liter 171 61 193 110 195 73 184 78 200 88 156 80
epinephrine, ng/liter 37 20 26 23 41 32 39 36 49 25 36 26
renin activity, ng/ml/hr 0.95 0.39 1.23 0.53 0.85 0.41 1.22 0.43a 0.82 0.44 1.08 o.5l
angiotensin II, ng/liter 13.1 5.0 16.6 6.4a 11.0 6.9 12.5 5.0 9.70 4.1 12.7 3.5k
aldosterone, ng/liter 62 25 115 59 73 46 169 86 82 64 143 84
Urinary sodium, mmol/24 hr 141 89 164 82 159 47 150 40 166 80 173 73
potassium, mmol/24 hr 71 33 161 48C 75 25 170 36C 67 24 159 53C
Creatinine clearance, mllmin/1.73 m2 95 18 99 22 99 25 102 28 93 17 97 15
a P < 0.05 versus basal dietary conditions (by paired t-test)
"P < 0.025 versus basal dietary conditions (by paired t-test)
P < 0.01 versus basal dietary conditions (by paired t-test)
dP < 0.025 versus normotensive members of normotensive or hypertensive families (by analysis of variance using the Bonferroni adjustment)
with borderline hypertension had repeated BP values between
140/90 and 160/95 mm Hg and sometimes below under outpa-
tient conditions, and secondary forms of hypertension were
excluded by the usual tests. No female subject was on hormonal
contraceptives. All subjects were informed about the investiga-
tive character of the study and gave their informed consent.
They were instructed to continue their usual diet but without
very salty foods or adding salt to their food, starting at least 14
days before the control study; using this dietary instruction, 24
hour urinary sodium and K excretions in 90 healthy subjects
studied previously averaged 136 and 65 mmol, respectively [28].
Special studies were performed after 14 days of basal dietary
condition and after 10 days of oral supplementation of the diet
with K, 100 mmollday, using slow tablets of potassium chlo-
ride, 0.75 g each, in three daily doses. Under both conditions,
24 hour urine was collected for determination of sodium, K
and creatinine excretion rates, and infusion of NE or All were
carried out in a morning after overnight fast with the partici-
pants resting throughout in a supine position [14, 19]. After a 60
minute equilibration period with slow intravenous infusion of
5% dextrose solution (0.1 ml/min), basal BP and heart rate were
measured and blood samples were drawn through an indwelling
intravenous cannula (placed at least 30 minutes previously on
the arm controlateral to the infusion) for determination of basal
plasma sodium, K, total calcium, creatinine, NE and epineph-
rifle. These basal measurements were obtained between 8 and 9
a.m. The dextrose solution was then replaced by a solution
containing levarterenol bitartrate in 5% dextrose (NE base, 10
to 20 sg/1iter). NE was infused at stepwise increasing dose rates
which were maintained for 20 minutes each. All subjects
received successive dose rates of 20, 40 and 100 ng/kg/min, and,
when the NE-induced increase in mean BP did not reach 20 mm
Hg, 200 ng/kg/min. During the last 10 minutes of each infusion
step, BP and heart rate were recorded every minute; at the end
of each infusion step blood samples were obtained from the arm
contralateral to the infusion for determination of NE. The NE
infusion was then replaced by 5% dextrose solution at slow rate
for 45 minutes. At the end of this second equilibration period,
BP and heart rate were measured and blood was drawn for
determination of plasma renin activity, aldosterone and All
levels. The dextrose solution was then replaced by a solution of
(Va15)-AII (Hypertensin, Ciba Geigy, Summit, New Jersey,
USA) in 5% dextrose (All, 1 to 2 pg/liter), which was infused at
stepwise increasing dose rates of 2, 4, and 10 ng/kg!min, and,
when the All-induced increase in diastolic BP did not reach 20
mm Hg, 20 ng/kg/min, for 20 minutes each. BP and heart rate
were monitored as described above, and blood samples were
obtained from the arm contralateral to the infusion at the end of
each infusion step for determination of plasma All and aldos-
terone concentrations.
Thereafter, the subjects were allowed to stand up for empty-
ing their bladder and having a light breakfast. After an addi-
tional 20 minute equilibration period during which the subjects
rested and received a slow intravenous infusion of 5% dextrose,
boli of 1, 2, 4 and 8 nmol isoproterenol hydrochloride (5 to 20
nmollliter) were injected and the heart rate was monitored
continuously. When the maximal increase in heart rate did not
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reach 30 beats/mm, further doses of 16 and 32 nmol isoproter-
enol were injected.
BP was measured with the automated recorder Physiometrics
SR 2, which detects Korotkoff sounds by microphone and
converts them to mechanical signals recorded on a graduated
disk. In a series of paired readings, this automated device did
not show marked deviations from readings by the standard
mercury sphygmomanometer [29]. Before each infusion study
with NE or All, respectively, the machine was mechanically
adjusted to give values equal to those of the mercury manom-
eter. Mean arterial pressure was calculated as the sum of
diastolic and one third of pulse pressure. Each recorded value
was the mean of at least eight measurements. For isoproterenol
sensitivity testing, the heart rate was continuously monitored
using an electrocardiogram; resting (pre-infusion) heart rate and
heart rate response to isoproterenol were calculated from the
three shortest R-R intervals before and following injection. The
chronotropic dose of isoproterenol that increased heart rate 25
beats/mm was obtained from dose—response curves relating
changes in heart rate to corresponding doses of isoproterenol.
Pressor effects of NE or All were assessed by plotting individ-
ual changes in mean (NE infusion study) or diastolic (All
infusion study) BP versus corresponding NE or All infusion
rates or associated changes in plasma NE or All concentra-
tions; the pressor dose of NE [16] or All [301 was defined as the
dose required to increase mean (NE) or diastolic (All) BP 20
mm Hg. Moreover, the increase in circulating NE or All to
elevate BP 20 mm Hg was calculated [81. The responsiveness of
plasma aldosterone to infused All was assessed by plotting
individual changes in plasma All versus corresponding changes
in plasma aldosterone; the increase in plasma All level neces-
sary to elevate plasma aldosterone by 200 ng/liter was derived.
As an appropriate index of baroreflex integrity, individual heart
rate responses during NE or All infusion were plotted against
the changes in mean BP; the heart rate response to an increase
in mean BP of 20 mm Hg was calculated [8]. The total plasma
clearance of NE or All was calculated dividing infusion rates by
the associated change in plasma concentration of NE or All,
respectively [8, 31]. The mean of three to four calculated
clearances was recorded, clearance values being similar during
lower and higher infusion rates [31]. Plasma and urinary sodium
and K were measured by flame photometer, creatinine by
autoanalyzer, total plasma calcium by atomic absorption spec-
trophotometry, NE and epinephrine by a radioenzymatic assay
[32], and plasma renin activity [33], All [34] and aldosterone
[351 by radioimmunoasay, as reported previously from this
laboratory [14, 36].
The three study groups were compared with each other by
analysis of variance using the Bonferroni adjustment [371, while
comparisons between the two study conditions were made by
two—tailed paired t-test [38]. The infused doses of NE or All
were cumulatively related with the corresponding blood levels
using bilogarithmic regressions. The calculated regression
equations were compared with each other by analysis of
covariance [39]. Many biological measurements follow a Gaus-
sian distribution only after logarithmic transformation [40]. For
this reason the homogeneity test of Pearson [411 was performed
both using absolute values or the natural logarithmic transfor-
mation. Based on this test the natural logarithmic transforma-
tion was used for analysis of doses and plasma levels of NE or
All, for plasma epinephrine, aldosterone and renin levels, as
well for doses of isoproterenol. Significance was assumed when
P < 0.05, and results are given as mean and standard deviation.
Results
Basal (pre-infusion) blood pressure, electrolytes and plasma
levels of endocrine variables
Under basal dietary conditions mean body weight and BP
were quite similar in the normotensive groups with negative or
positive FHH (Table 1). Body weight tended to be slightly
higher in the patients with borderline hypertension. Heart rate,
urinary excretion rates of sodium and K, creatinine clearance,
and plasma levels of sodium, K, calcium, NE, epinephrine,
renin activity, All and aldosterone did not differ significantly
among the three groups.
Following supplementation with K, 100 mmollday, urinary
K excretion rates increased at a comparable degree in the
normotensive subjects with negative (by 90 31 mmol/day) or
positive FHH (by 95 25 mmol/day) and patients with border-
line hypertension (by 92 29 mmol/day) (Table 1). Systolic,
diastolic and mean BP were unchanged in normotensive sub-
jects with negative FHH. However, systolic BP decreased
significantly (P < 0.05) in normotensive members of hyperten-
sive families (—4 5 mm Hg) and patients with borderline
hypertension (—5 5 mm Hg), and a similar tendency was
noted for diastolic (—3 7 mm Hg, NS, and —4 8 mm Hg, P
<0.05, respectively) and mean BP (—4 9mm Hg, NS, and —5
8 mm Hg, P < 0.05, respectively). Plasma K, aldosterone
and renin activity rose significantly (P < 0.05 to <0.025) in all
study groups, plasma All also tended to increase. Body weight,
creatinine clearance, plasma and urinary sodium, and plasma
calcium, NE and epinephrine values were not significantly
changed during high K intake (Table 1).
Metabolism of infused norepinephrine or angiotensin II
The metabolism of infused NE or All, judged both by their
total plasma clearance and by the relationship between cumu-
lated infusion rates and concomitant plasma concentration
(Table 2), did not differ among the three study groups. More-
over, high K intake did not significantly modify these varia-
bles.
Effects of norepinephrine or angiotensin II infusion
During basal K intake, the dose of infused NE required to
elevate mean BP 20 mm Hg was reduced by 30% in
normotensive members of hypertensive families and by 48% in
borderline hypertensive patients (Table 3) as compared with
normotensive subjects with negative FHH; the amount of
plasma NE required to elevate mean BP 20 mm Hg was in the
two former groups decreased by 50% and 38%, respectively.
The dose of infused All required to elevate diastolic BP 20 mm
Hg, the amount of plasma All required to elevate diastolic BP
20 mm Hg, and the changes in plasma All associated with an
increase in plasma aldosterone of 200 ng/liter were comparable
in all study groups.
Compared with basal dietary conditions, a high K diet
increased, in the normotensive members of hypertensive fami-
lies and patients with borderline hypertension, the pressor dose
of infused NE by 68% and 35%, respectively, and the amount of
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Table 2. Calculated total plasma clearance (mean so), and intercept and correlation coefficient of bilogarithmic regressions relating
cumulated infused doses and corresponding blood levels of norepinephrine or angiotensin II obtained during infusion studies
Norepinephrine infusion Angiotensin IL infusion
Plasma Plasma
clearance Correlation clearance Correlation
mi/mm/kg Intercept Slope coefficient mi/mm/kg Intercept Slope coefficient
Normotensive members of normotensive
families (N 12)
basal potassium diet 88 38 2.51 0.95 0.91 105 43 2.78 0.91 0.90
high potassium diet 98 31 2.56 0.93 0.78 108 57 3.01 0.80 0.84
Normotensive members of hypertensive
families (N = 12)
basal potassium diet 90 28 2.25 0.84 0.76 119 50 2.52 1.01 0.87
high potassium diet 104 34 2.23 0.79 0.78 117 71 2.83 0.87 0.90
Patients with borderline essential
hypertension (N = 11)
basal potassium diet 79 37 2.69 1.02 0.78 129 77 2.42 1.09 0.79
high potassium diet 94 45 2.55 0.96 0.85 102 46 2.80 0.86 0.91
Calculated clearance values were compared with each other by paired t-test (comparison between the two study conditions) and analysis of
variance using the Bonferroni adjustment (comparison among the three study groups) and were found not to differ. Regression equations were
compared with each other by analysis of covariance according to Duncan and not found to differ significantly. All regressions were statistically
significant (P < 0.001).
Table 3. Pressor and endocrine effects of exogenous norepinephrine or angiotensin II (mean SD)
Normotensive members of .Patients with boderhne
essential hypertensionnormotensiye families hypertensiye families
basal K high K basal K high K basal K high K
diet diet diet diet diet diet
N 12 12 11
Dose of infused norepinephrine to elevate mean
arterial pressure 20mm Hg, ng/kg/min 134 81 120 94 96 43 125 6l 69 34" 118 56"
Increase in plasma norepinephrine to elevate
mean arterial pressure 20mm Hg, ng/iiter 1675 1082 1607 1150 829 410" 1489 981" 1015 676C 1670 1167b
Dose of infused angiotensin II to elevate diastolic
arterial pressure 20mm Hg, ng/kg/min 10.3 6.4 9.5 4.7 8.4 3.3 10.0 5.3 11.2 6.8 8.9 4.9
Increase in plasma angiotensin II to elevate
diastolic arterial pressure 20mm Hg, ng/liter 139 108 108 51 120 65 130 111 141 74 134 96
Increase in plasma angiotensin IL associated with
an increase in plasma aldosterone of 200
ng/liter ng/liter 126 49 85 48" 132 72 96 60b 115 52 80 39
a P < 0.05 versus basal dietary conditions (by paired t-test)
b p < 0.025 versus basal dietary conditions (by paired t-test)
P < 0.05 versus normotensive members of normotensive families (by analysis of variance using the Bonferroni adjustment)
P < 0.025 versus normotensive members of normotensive families (by analysis of variance using the Bonferroni adjustment)
plasma NE associated with this pressor response by 62% and
75%, respectively (Table 3). Thus, both variables returned to
the values observed in normotensive subjects without FHH
during basal K intake. While in this normotensive control
group, pressor effects of NE were not modified by the high as
compared with basal K intake. Correspondingly, the curve
relating changes in plasma NE and concomitant increases in
mean BP following NE dose rates of 20, 40 and 100 ng/kg/min
(the three infusion rates that each subject received) was unal-
tered in normotensive subjects with negative FHH and dis-
placed to the right (towards values obtained in the normoten-
sive control group) in normotensive members of hypertensive
families and patients with borderline hypertension (Fig. 1). This
displacement was statistically significant (P < 0.05) at the dose
rate of 100 nglkg/min.
Compared with basal dietary conditions, K supplementation
did not significantly modify the dose of infused All or the
increase in circulating All required to elevate diastolic BP by 20
mm Hg in the three study groups (Table 3). The curve relating
changes in plasma All and concomitant increases in diastolic
B? following All dose rates of 2, 4 and 10 ng/kg/min (the three
infusion rates that each subjects received) was also not signif-
icantly altered (Fig. 2).
Compared with basal K intake the increase in plasma All
required to elevate the plasma aldosterone level by 200 ng/liter
was reduced similarly (P < 0.05 to < 0.025) during a high K
intake in normotensive sUbjects with negative (—33%) or posi-
tive FHH (—27%) families and patients with borderline hyper-
tension (—30%). The curve relating plasma All and concomi-
tant plasma aldosterone levels before and during All infusion at
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Plasma norepinephrine, pg/liter
Fig. 1. Relationship between A plasma norepinephrine and A mean
arterial pressure during norepinephrine infusion at stepwise increasing
dose rates of 20, 40 and 100 ng/kg/min under basal dietary conditions
(closed circles) or after dietary supplementation with potassium (open
circles) in the three study groups. The far left symbol represents values
at the end of the first norepinephrine infusion step; symbols thereafter
represent data at the end of the following infusion steps. Bars represent
the sD; some bars have been omitted for clarity; * P < 0.05 versus
dietary control conditions.
Plasma angiotensin II, ng/liter
Fig. 3. Relationship between plasma angiotensin II and plasma aldos-
terone before and during angiotensin II infusion at stepwise increasing
dose rates of 2, 4 and 10 ng/kg/min under basal dietary conditions
(closed circles) or after dietary supplementation with potassium (open
circles) in the three study groups. The far left symbol represents basal
measurements before angiotensin II infusion; symbols thereafter rep-
resent data at the end of each successive infusion step of angiotensin II.
Bars represent the so; some bars have been omitted for clarity; *D <
0.05; P < 0.025 versus dietary control conditions.
Normotensive families Hypertensive families Borderline
30 hypertensionLI
10 20 50 1002001020 50 1002001020 50 100200
A Plasma angioterisin II, ng/liter
Fig. 2. Relationship between A plasma angiotensin II and A diastolic
arterial pressure during angiotensin II infusion at step wise increasing
dose rates of 2, 4 and 10 ng/kg/min under basal dietary conditions
(closed circles) or after dietary supplementation with potassium (open
circles) in the three study groups. The far left symbol represents values
at the end of the first angiotensin II infusion step; symbols thereafter
represent data at the end of the following infusion steps. Bars represent
the so; some bars have been omitted for clarity.
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bers of hypertensive families as well as patients with borderline
hypertension a characteristic regulatory abnormality, namely,
the pressor hyperresponsiveness to NE relative to endogenous
plasma NE levels [13, 16—19]. In both groups the dietary
K -induced improvement in cardiovascular NE hyperreactivity
was accompanied by a slight decrease in BP. In contrast, an
augmented potassium intake did not modify BP or NE respon-
siveness in normotensive control subjects with negative FHH,
nor did it significantly alter All pressor reactivity relative to
circulating All in any of the three groups. These observations
are consistent with a K-remediable disturbance in NE- but not
All-mediated regulation in the pathogenesis of essential hyper-
tension.
K is obviously a relevant factor in BP regulation. Our
observations complement previous reports of an ameliorating
effect of a high K intake on BP in experimental or spontaneous
hypertension [1—5], in some [6, 8—12] but not all [42] studies of
human essential hypertension, and in normotensive offspring of
hypertensive families [6—8], particularly when K was added to
a high sodium diet [12].
K may in fact interact with various BP-regulating compo-
nents. As expected [43, 44], basal plasma renin, All and al-
dosterone levels, as well as the responsiveness of aldosterone
to All, were increased in the present study during high as
compared with a lower K intake. Nevertheless, since these
adaptive changes were of similar magnitude in the three groups
and pressor responses to infused All seemed to remain largely
commensurate for circulating plasma All concentrations, the
preferential BP-lowering effect of high K diet in normotensive
subjects with a positive FHH and borderline hypertensive
patients could not be explained by a modification in angi-
otensinergic or aldosterone—mediated BP control. Pressor ef-
fects of All were previously noted to be blunted following
dietary K supplementation in some patients with essential
hypertension [26] and following treatment of potassium deple-
tion in hemodialysis patients (P. Weidmann, M.H. Maxwell,
dose rates of 2, 4 and 10 pmol/kg/min was significantly (P <
0.05) displaced upwards (Fig. 3).
Responses of heart rate
The heart rate responses to boli of isoproterenol or to rises in
BP induced by infusion of NE or All were quite similar in the
three study groups during basal K intake and were not
significantly modified by a high K diet (Table 4).
Discussion
The present findings indicate that supplementation of a usual
"modern man" diet with K improves in normotensive mem-
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Table 4. Heart rate responses to isoproterenol boll or rise in arterial pressure during infusion with norepinephnne
or angiotensin II (mean SD)
Normotensive members of •Patients with borderline
essential hypertensionnormotensiye families hypertensive families
basal K high K basal K + high K + basal K high K
diet diet diet diet diet diet
N 12 12 11
Isoproterenol bolus dose to increase heart rate by 25
beats/mm, pmol/kg 107 73 120 84 99 65 78 61 102 91 86 59
Heart rate change associated with a rise in mean
arterial pressure of 20 mm Hg during norepi-
nephrine infusion study, beats/mm —9.4 6.5 —8.1 5.6 —12.1 5.8 —11.7 4.5 —10.0 7.0 —10.8 6.6
Heart rate change associated with a rise in mean
arterial pressure of 20 mm Hg during angiotensin II
infusion study, beats/mm —5.2 3.1 —5.5 3.6 —6.3 4.0 —7.0 3.9 —5.0 3.1 —4.8 3.5
unpublished observations); nevertheless, the lack of simulta-
neous plasma All measurements does not allow ajudgement of
the net influence of K on integrated angiotensinergic control in
these studies. The differential influence of K on vascular and
adrenal—cortical responsiveness to All in all three groups in the
present investigation is probably related to a varying response
of All receptor number or affinity in the two target organs [45,
46]. With regard to adrenergic BP regulation, it has been
suggested that dietary K supplementation might, in patients
with essential hypertension and subjects with positive FHH,
also slightly lower plasma NE [6, 10]. However, plasma con-
centrations of epinephrine and NE as well as heart rate were not
altered by high K intake in the present and some previous
studies [7, 261.
Several additional factors must be considered as potential
mechanisms of the K-mediated improvement in pressor re-
sponsiveness to NE in the FHH positive setting of "pre-
hypertension" and in borderline hypertension. These include
the uptake of NE into sympathetic nerve terminals, the plasma
clearance of NE [31], the sensitivity of the baroreflex, the body
sodium—blood volume state [47], morphological changes in the
blood vessel wall/lumen ratio [48], and a functional change of
cardiovascular adrenergic receptors or intracellular compo-
nents. Some controversed data suggest that the neuronal
reuptake of NE may be enhanced by K [10, 49]. The relation-
ship between NE infusion rates and concomitant plasma NE
levels and the plasma NE clearance were unaltered during
dietary K supplementation in our three study groups, thus
providing little support for this hypothesis. The baroreflex
sensitivity, as judged from responses of heart rate to NE-
induced rises in arterial BP, was also not modified. A previous
report of augmented baroreflex sensitivity during dietary K
supplementation in 10 normotensive members of hypertensive
families is difficult to judge, since NE was infused during five
minutes only [7]. The latter may not have allowed achievement
of a steady state for NE and BP levels, while the 20 minute
duration of each NE infusion step in the present study should
fulfill this prerequisite. Body sodium tends to decrease during
K loading [2, 9, 26]. In our study groups, plasma and urinary
sodium values and body weight were not consistently changed
after 10 days of high K intake, thus indicating that extracellu-
lar sodium—fluid volume depletion could not explain the selec-
tive effect of K supplementation on NE reactivity and BP
observed in normotensive subjects with positive FHH or par-
ents with borderline hypertension. The same conclusion applies
to pressure elicited variations in vascular wall thickness [48]
which are not likely to exist already, and account for the
selective NE hyperreactivity in the FHH positive setting of
pre-hypertension and which, if they existed, would hardly be
reversed within 10 days of high K intake only.
Considering these aspects and the lack of an effect of K
supplementation on cardiac beta—receptor responsiveness, ob-
served improvements in NE reactivity were probably at least in
part mediated by functional changes of resistance vessels.
Electrophysiological studies indicate that K stimulates a cel-
lular electrogenic pump, thereby hyperpolarizing the membrane
and reducing calcium influx [49]. In fact elevation of extracel-
lular K within the physiological range lowered the resistance
to blood flow of intact vascular bed and caused relaxation of
isolated, vascular smooth muscle [25, 501, Furthermore, K
antagonized the vasoconstrictor effect of NE or acetylbetaeth-
ylcholine [51, 52]. In contrast, the influence of K on the
responsiveness of blood vessels to other vasoactive agents,
including All, is more controversial [49]. The differential effects
of dietary K supplementation on NE as compared with the
All-dependent BP control observed in the present study in
pre-hypertensive subjects possibly indicate that the membrane
hyperpolarization induced by K selectively closed the calcium
channels affected by NE but not those affected by All. This
hypothesis is sustained by the observation that NE induced
vasoconstriction depends more on intracellular calcium than
that induced by All [53, 54]. Moreover, chronic pharmacolog-
ical blockade of cellular calcium entry lowered in normotensive
or borderline hypertensive subjects pressor—responsiveness to
NE but not All [55].
A disturbance in noradrenergic regulation seems to play an
important role in the pathogenesis of essential hypertension.
Alterations that may alone or concomitantly raise BP, include
an increased central and/or peripheral sympathetic activity [56,
57], an alteration in cardiovascular adrenergic receptors [57,
58], enhanced receptor—effector coupling [59, 60], as well as
secondary elevation in blood vessels reactivity due to hyper-
tension—induced wall thickening [47]. The present study does
not allow discrimination of whether the exaggerated NE reac-
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tivity in normotensive members of hypertensive families [13,
14] or patients with essential hypertension [18] is promoted by
dietary K deficiency, or whether the beneficial effect of K
supplementation on NE responsiveness is rather unspecific.
Whatever the exact interactions at the cellular level, a familial
occurrence of NE hyperreactivity relative to existing sympa-
thetic activity may predispose for the development of essential
hypertension. Moreover, a selective improvement in norad-
renergic control without lowered angiotensinergic influence
may in turn be an important common principle underlying the
antihypertensive action of such various treatments as dietary
K supplementation, thiazide—type agents [19, 61], calcium
channel blockers [55] or sympatholytics [17, 621.
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